HDAC9 and amyotrophic lateral sclerosis: Another HDAC inhibitor is the valproic acid (VPA) that, when administered to transgenic ALS SOD1 mice, has been shown to not improve survival or motor performance but to slightly delay the onset of motor decline, without being able to prevent disruption of NMJ [119,120].